source
- Degron Therapeutics raises $40M in Series A extension, total $95M, as Cabaletta releases early CAR‑T dataDegron Therapeutics, a US‑China biotech focused on molecular‑glue degrader technology, announced an additional $40 million in Series A extension funding, bringing its total capital raised to $95 mi…
- Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…